ImmunityBio Responds to FDA OPDP Letter, Announces Comprehensive Compliance Initiatives

Key Highlights for Investors

• ImmunityBio (NASDAQ: IBRX) responded to the FDA’s Office of Prescription Drug Promotion (OPDP) regarding advertising concerns involving a podcast and a television advertisement.
• The company confirmed the television ad in question was never broadcast, aired, or disseminated to the public.
• An identified podcast was removed from ImmunityBio’s website and the company has formally requested its removal from all third-party platforms.
• ImmunityBio is implementing a robust suite of corrective actions and compliance enhancements, including executive training, expanded review protocols, and external regulatory oversight.
• The company reaffirmed its commitment to advertising compliance and transparency with regulators.
• Detailed background was provided to clarify the scientific context of statements made by founder Dr. Patrick Soon-Shiong during a podcast appearance.
• The company highlighted that all references to investigational drugs were aspirational and grounded in independent scientific assessments and FDA-authorized programs.

Detailed Analysis and Potential Price-Sensitive Information

ImmunityBio, a clinical-stage immunotherapy company, has taken decisive action in response to an FDA OPDP letter dated March 13, 2026, which raised concerns about the company’s promotional communications related to their oncology drug, ANKTIVA^® (nogapendekin alfa inbakicept-pmln). The FDA cited a podcast and a television advertisement, questioning whether the company’s communications adhered to FDA regulations for prescription drug promotion.

Key points for shareholders and potential impact on share value:

• Regulatory Scrutiny and Compliance Enhancements: ImmunityBio’s prompt response to the FDA and its implementation of enhanced advertising compliance protocols mitigate the risk of future regulatory violations. The company’s actions include:
  • Mandatory executive training on advertising compliance
  • Expanded Promotional Review Committee (PRC) protocols
  • Engagement of external regulatory counsel to audit high-visibility communications

  These measures are likely to restore confidence among investors and regulators, reducing the risk of reputational or financial penalties.

• No Public Dissemination of Television Advertisement: ImmunityBio confirmed that the cited television ad was never aired or disseminated, which significantly limits potential regulatory or legal repercussions.
• Remediation of Podcast Content: The company has already removed the podcast from its corporate website and is actively ensuring it is taken down from third-party sites, demonstrating swift corrective action.
• Commitment to Accurate and Balanced Communications: The company emphasized that all future promotional materials for ANKTIVA^® will be compliant, accurate, and balanced, underscoring a proactive stance in regulatory affairs.
• Clarification of Scientific Statements: ImmunityBio clarified that the statements made by Dr. Soon-Shiong during the podcast were intended to discuss the scientific and aspirational potential of their immunotherapy pipeline, not to promote unapproved uses or exaggerate claims. The company cited independent evaluations by the National Cancer Institute and referenced peer-reviewed scientific publications to support its statements.
• Risks of Non-Compliance and Forward-Looking Statements: The press release contains cautionary statements about the company’s ability to fully implement corrective actions and notes that successful remediation depends on cooperation from third parties. Investors should note the potential risks associated with regulatory compliance and the forward-looking nature of the company’s statements.

About ANKTIVA^® (nogapendekin alfa inbakicept-pmln)

ANKTIVA^® is an interleukin-15 (IL-15) receptor agonist approved in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The drug acts by stimulating NK and CD8+ killer T cells, which are crucial in targeting and destroying cancer cells.

Important safety information includes:

• Risk of metastatic bladder cancer with delayed cystectomy; timely consideration of surgery is critical if patients do not respond to treatment.
• ANKTIVA^® is for intravesical use only and should not be administered subcutaneously or intravenously.

Please refer to the full prescribing information for detailed safety and administration guidelines.

About ImmunityBio

ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies to activate both the adaptive and innate immune systems. Its core platform, Cancer BioShield™, aims to stimulate natural killer cells, cytotoxic T cells, and memory T cells through a proprietary IL-15 superagonist. The company’s pipeline includes a range of investigational immunotherapies, including adenovirus-vectored vaccines and NK-cell therapies.

Investor Considerations

ImmunityBio’s prompt and transparent response to the FDA, along with its comprehensive compliance overhaul, are positive signals for investors concerned about regulatory risks. The company’s clear communication of its corrective actions and the absence of public dissemination of the cited advertisement reduce the likelihood of significant penalties or reputational damage. This commitment to compliance and regulatory best practices could help support or improve share value, especially as ImmunityBio continues to advance its oncology pipeline and commercial strategy.

Company Contacts

Investors: Hemanth Ramaprakash, PhD, MBA, +1 858-746-9289, [email protected]
Media: Sarah Singleton, +1 415-290-8045, [email protected]

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as described in ImmunityBio’s filings with the SEC. Investors are encouraged to review the full risk disclosures before making investment decisions. The author and publisher assume no responsibility for any actions taken based on the information provided.

View ImmunityBio, Inc. Historical chart here